Autor: |
Olga P. Nyssen, Pietro Pratesi, Miguel A. Spínola, Laimas Jonaitis, Ángeles Pérez-Aísa, Dino Vaira, Ilaria Maria Saracino, Matteo Pavoni, Giulia Fiorini, Bojan Tepes, Dmitry S. Bordin, Irina Voynovan, Ángel Lanas, Samuel J. Martínez-Domínguez, Enrique Alfaro, Luis Bujanda, Manuel Pabón-Carrasco, Luis Hernández, Antonio Gasbarrini, Juozas Kupcinskas, Frode Lerang, Sinead M. Smith, Oleksiy Gridnyev, Mārcis Leja, Theodore Rokkas, Ricardo Marcos-Pinto, Antonio Meštrović, Wojciech Marlicz, Vladimir Milivojevic, Halis Simsek, Lumir Kunovsky, Veronika Papp, Perminder S. Phull, Marino Venerito, Lyudmila Boyanova, Doron Boltin, Yaron Niv, Tamara Matysiak-Budnik, Michael Doulberis, Daniela Dobru, Vincent Lamy, Lisette G. Capelle, Emilija Nikolovska Trpchevska, Leticia Moreira, Anna Cano-Català, Pablo Parra, Francis Mégraud, Colm O’Morain, Guillermo J. Ortega, Javier P. Gisbert, on behalf of the Hp-EuReg Investigators |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Antibiotics, Vol 12, Iss 9, p 1427 (2023) |
Druh dokumentu: |
article |
ISSN: |
2079-6382 |
DOI: |
10.3390/antibiotics12091427 |
Popis: |
The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the “most important” variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|